[go: up one dir, main page]

CL2004001068A1 - Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer. - Google Patents

Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
CL2004001068A1
CL2004001068A1 CL200401068A CL2004001068A CL2004001068A1 CL 2004001068 A1 CL2004001068 A1 CL 2004001068A1 CL 200401068 A CL200401068 A CL 200401068A CL 2004001068 A CL2004001068 A CL 2004001068A CL 2004001068 A1 CL2004001068 A1 CL 2004001068A1
Authority
CL
Chile
Prior art keywords
preparation
oxazepina
tetrahydrobenzo
alzheimer
disease
Prior art date
Application number
CL200401068A
Other languages
English (en)
Inventor
Guido Galley
Robert Alan Goodn
Jens-Uwe Peters
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2004001068A1 publication Critical patent/CL2004001068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL200401068A 2003-05-19 2004-05-17 Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer. CL2004001068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011040 2003-05-19

Publications (1)

Publication Number Publication Date
CL2004001068A1 true CL2004001068A1 (es) 2005-04-15

Family

ID=33442730

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401068A CL2004001068A1 (es) 2003-05-19 2004-05-17 Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.

Country Status (19)

Country Link
US (1) US7060698B2 (es)
EP (1) EP1631296B1 (es)
JP (1) JP4510021B2 (es)
KR (1) KR100731368B1 (es)
CN (1) CN1794997B (es)
AR (1) AR044363A1 (es)
AT (1) ATE360424T1 (es)
AU (1) AU2004238037B2 (es)
BR (1) BRPI0410647A (es)
CA (1) CA2524640C (es)
CL (1) CL2004001068A1 (es)
DE (1) DE602004006118T2 (es)
ES (1) ES2285458T3 (es)
MX (1) MXPA05012368A (es)
MY (1) MY143953A (es)
PL (1) PL1631296T3 (es)
RU (1) RU2332408C2 (es)
TW (1) TWI290550B (es)
WO (1) WO2004100958A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
CN101115730A (zh) * 2004-12-14 2008-01-30 阿斯利康(瑞典)有限公司 新分子探针
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8855099B2 (en) 2007-03-19 2014-10-07 Qualcomm Incorporated Selective phase connection establishment
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
RU2345078C1 (ru) * 2007-06-19 2009-01-27 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция, способ получения
JP5275315B2 (ja) * 2010-10-01 2013-08-28 学校法人近畿大学 新規化合物及びβ−セクレターゼ阻害剤
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
NO3175985T3 (es) * 2011-07-01 2018-04-28
US11649218B2 (en) 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
ES2239788T3 (es) * 1996-12-06 2005-10-01 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima de conversion de la interleuquina-1-beta.
CA2413429A1 (en) 2000-06-23 2001-12-27 Takeda Chemical Industries, Ltd. Benzoxazepinones and their use as squalene synthase inhibitors
JP2002080468A (ja) * 2000-06-23 2002-03-19 Takeda Chem Ind Ltd ベンゾオキサゼピン化合物
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
US7060798B2 (en) * 2002-05-13 2006-06-13 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Modified protein adhesives and lignocellulosic composites made from the adhesives
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives

Also Published As

Publication number Publication date
JP4510021B2 (ja) 2010-07-21
MXPA05012368A (es) 2006-02-02
JP2007501261A (ja) 2007-01-25
AR044363A1 (es) 2005-09-07
EP1631296B1 (en) 2007-04-25
KR100731368B1 (ko) 2007-06-21
US7060698B2 (en) 2006-06-13
TWI290550B (en) 2007-12-01
TW200510355A (en) 2005-03-16
KR20060003107A (ko) 2006-01-09
CN1794997A (zh) 2006-06-28
ES2285458T3 (es) 2007-11-16
AU2004238037B2 (en) 2009-11-26
RU2005139529A (ru) 2006-08-10
ATE360424T1 (de) 2007-05-15
DE602004006118T2 (de) 2008-01-03
PL1631296T3 (pl) 2007-08-31
CA2524640C (en) 2011-10-11
US20040235819A1 (en) 2004-11-25
EP1631296A1 (en) 2006-03-08
BRPI0410647A (pt) 2006-07-04
RU2332408C2 (ru) 2008-08-27
CN1794997B (zh) 2010-05-12
DE602004006118D1 (de) 2007-06-06
AU2004238037A1 (en) 2004-11-25
CA2524640A1 (en) 2004-11-25
WO2004100958A1 (en) 2004-11-25
MY143953A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
EP1789075A4 (en) ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
SV2003001107A (es) Imidazotriazinas ref.lea 35368
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
CL2004001347A1 (es) Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor
CL2004001365A1 (es) Compuestos derivados de 3-fluoropiperidina; composicion farmaceutica que lo comprende; y uso del compuesto para tratar o prevenir el dolor o la enfermedad de parkinson.
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
DE60200023D1 (de) Isoindoloindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltende pharmazeutische Zusammensetzungen
ZA200510138B (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
CL2004001262A1 (es) Composicion farmaceutica que comprende lamivudina, zidovudina y efavirenz, o derivados de ellos; kit farmaceutico; procedimiento para su preparacion; y uso en la preparacion de un medicamento para el tratamiento o prevencion de infecciones virales, e
CL2004001607A1 (es) Uso de gabaxafol para preparar un medicamento util en el tratamiento de la depresion.
CL2004001263A1 (es) Composicion farmaceutica que comprende lamivudina, estavudina y efavirenzo, o derivados de ellos, kit farmaceutico; procedimiento para su preparacion; y uso en la preparacion de un medicamento para el tratamiento o prevencion de infecciones virales,
ITTO20050691A1 (it) Uso di neboglamine nella terapia delle tossicodipendenze
TH54045A3 (th) อิมิแดซอลไตรเอซอลอพิริมิดิโนนชนิดใหม่ ขบวนการสำหรับการเตรียมสารเหล่านี้และการใช้ประโยชน์ในการเป็นสารผสมเชิงเภสัชกรรม